Advertisement
Screener

Zoetis Inc. (ZTS) Overview

Zoetis Inc. (ZTS) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 1.65; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual 1.42; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 1.63; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 1.63; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$66.78$77.24$89.34$103.33$119.52$138.242025-11-062026-11-06$66.78$87.60$114.91$150.73$197.73$259.382021-11-082026-11-06$46.40$65.87$93.50$132.73$188.43$267.492016-11-072026-11-06$26.98$42.95$68.37$108.83$173.25$275.782013-02-012026-11-06$26.98$42.95$68.37$108.83$173.25$275.782013-02-012026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$79.43
Previous close
$70.30
Change
$9.13
Change (%)
12.99%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

ZTS
-43.24%
S&P 500
(m)

1 year

ZTS
-49.90%
S&P 500
(m)

3 years

ZTS
-57.89%
S&P 500
(m)

5 years

ZTS
-61.85%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 1.65

1.261.401.541.691.8331 Mar 2025: estimate (m); actual 1.3431 Mar 2025(m)30 Jun 2025: estimate (m); actual 1.6330 Jun 2025(m)30 Sept 2025: estimate (m); actual 1.6330 Sept 2025(m)31 Mar 2026: estimate (m); actual 1.4231 Mar 2026(m)30 Jun 2026: estimate (m); actual 1.6530 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)1.65(m)(m)
1 Jan 202631 Mar 2026(m)1.42(m)(m)
1 Jul 202530 Sept 2025(m)1.63(m)(m)
1 Apr 202530 Jun 2025(m)1.63(m)(m)
1 Jan 202531 Mar 2025(m)1.34(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 6.02

4.194.695.195.706.2031 Dec 2021: estimate (m); actual 4.2731 Dec 2021(m)31 Dec 2022: estimate (m); actual 4.4931 Dec 2022(m)31 Dec 2023: estimate (m); actual 5.0731 Dec 2023(m)31 Dec 2024: estimate (m); actual 5.4731 Dec 2024(m)31 Dec 2025: estimate (m); actual 6.0231 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)6.02(m)(m)
1 Jan 202431 Dec 2024(m)5.47(m)(m)
1 Jan 202331 Dec 2023(m)5.07(m)(m)
1 Jan 202231 Dec 2022(m)4.49(m)(m)
1 Jan 202131 Dec 2021(m)4.27(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 2.47B ■ Earnings 0.69B — Profit margin 28.00%

-0.30B24.3%0.72B26.5%1.74B28.8%2.76B31.0%30 Sept 2025: revenue 2.40B; earnings 0.72B; profit margin 30.04%30 Sept 202531 Dec 2025: revenue 2.39B*; earnings 0.60B*; profit margin 25.26%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 2.26B; earnings 0.60B; profit margin 26.57%31 Mar 202630 Jun 2026: revenue 2.47B; earnings 0.69B; profit margin 28.00%30 Jun 2026

31 Dec 2025 ■ Revenue 9.47B ■ Earnings 2.67B — Profit margin 28.23%

-1.14B25.2%2.78B26.5%6.69B27.9%10.60B29.2%31 Dec 2022: revenue 8.08B; earnings 2.11B; profit margin 26.16%31 Dec 202231 Dec 2023: revenue 8.54B; earnings 2.34B; profit margin 27.43%31 Dec 202331 Dec 2024: revenue 9.26B; earnings 2.49B; profit margin 26.86%31 Dec 202431 Dec 2025: revenue 9.47B; earnings 2.67B; profit margin 28.23%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$79.43(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$79.43High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning ZTS

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
4.52M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-3.36%*
Total return · month
-9.04%*
Total return · quarter
-3.34%*
Total return · half year
-37.26%*
Total return · year to date
-43.24%*
Total return · 1 year
-49.90%*
Total return · 3 years
-57.89%*
Total return · 5 years
-61.85%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

Zoetis Inc. Overview

View more →

(m)

(m)

SEC CIK
1555280
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
10 SYLVAN WAY, PARSIPPANY, New Jersey, 07054, United States
Fiscal year end
1231
Phone
973-822-7000

Similar stocks

Stock NameCountryMarket CapPE Ratio
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10